Orum Therapeutics, Inc. · KRX:475830
Orum Therapeutics — Investor Presentation (2026)
31 slides from Orum Therapeutics's investor presentation, 2026
Slide 1: Targeted Delivery of Degrader Payloads
Orum's Proprietary DAC Platforms Targeted Delivery of Degrader Payloads 2026 Q4
Slide 2: Disclaimer
Disclaimer Forward-looking Statements This presentation contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this presentation regarding matters that are not historical facts, including, but not limited to, stat
Slide 3: Orum: Clinical-Stage DAC Development and New Payload Discovery
Orum: Clinical-Stage DAC Development and New Payload Discovery Daejeon, KR Boston, US Bioconjugation Antibody Oncology Discovery Pharmacology First company to develop a Innovative and proprietary Three FDA IND packages clinical stage DAC platform technologies Current pipeline focus: Bioassay Medicin
Slide 4: Robust CAGR Expected in ADC Market Amid Increasing Demand for Novel MoA Payload
Robust CAGR Expected in ADC Market Amid Increasing Demand for Novel MoA Payload Market expected to reach $28B by 2028 (23% CAGR), with ADCs accounting for 30% of global biopharma licensing agreements Success of maytansinoids, auristatins, and campothecin payload ADC payload types classes has ushered
Slide 5: What is a Degrader-Antibody Conjugate (DAC)?
What is a Degrader-Antibody Conjugate (DAC)? Antibody-directed delivery of degrader payloads to intracellular proteins Conventional ADC VS Orum DAC Antibody Confers selectivity and binding against cell surface antigen, allowing targeted delivery to target cell Linker Connects payloads to antibody wi
Slide 6: DAC Mechanism of Action: Targeted Delivery and Intracellular Protein Degradation
DAC Mechanism of Action: Targeted Delivery and Intracellular Protein Degradation Selective tumor targeting combined with targeted protein degradation drives tumor cell death 1 2 3 4 5 Targeted delivery & Intracellular release of Degrader-mediated Polyubiquitination of Proteasomal internalization deg
Slide 7: Proprietary DAC Approach Uniquely Positions Orum Amongst Competitors
Proprietary DAC Approach Uniquely Positions Orum Amongst Competitors Orum's DAC approach combines the specificity of antibody-drug conjugation with the robust efficacy potential of targeted protein degradation Orum DAC Protein degrader conjugated to antibody STRENGTHS STRENGTHS Clinically validated
Slide 8: Multiplatform Pipeline to Address High Unmet Medical Need
Multiplatform Pipeline to Address High Unmet Medical Need Orum’s proprietary DAC platforms Platform Program Target Indication Discovery IND-enabling Phase 1 AML, ORM-1153 CD123 Heme-onc GSPT1 Platform ORM-1023 Undisclosed SCLC, NET Multiple Undisclosed Solid Tumors New Payloads Immunology & Multiple
Slide 9: GSPT1 Platform
GSPT1 Platform Antibody-enabled Molecular Glues • ORM-1153 | R/R AML, Phase 1 • ORM-1023 | SCLC & NET, Discovery
Slide 10: GSPT1 Degraders Are Highly Potent Against a Broad Set of Tumor Types
GSPT1 Degraders Are Highly Potent Against a Broad Set of Tumor Types GSPT1 is a housekeeping protein involved in In vitro screen of GSPT1 degrader translation termination against 250+ cell lines across 20+ tumor types Degradation of GSPT1 → Integrated stress response → Prolonged response Hematologic
Slide 11: ORM-1153: CD123-Targeting GSPT1 DAC
ORM-1153: CD123-Targeting GSPT1 DAC Combining CD123-targeted delivery with GSPT1 degradation Antigen target: Antibody CD123 Orum’s proprietary Fc-silenced Highly expressed in AML, CD123 antibody with enhanced >97% at diagnosis | >98% at relapse internalization and cross-reactivity Low expression in
Slide 12: ORM-1153: Opportunity in Acute Myeloid Leukemia (AML)
ORM-1153: Opportunity in Acute Myeloid Leukemia (AML) Unmet Needs AML Market Size (global) & Patient Age Trends Market projected to grow from $3.5B in ‘24 to $9.6B Improving efficacy for Significantly lower efficacy in relapsed/refractory patients by ‘34 (10.6% CAGR), with North America making R/R p
Slide 13: Design Changes Incorporated into ORM-1153
Design Changes Incorporated into ORM-1153 ORM-5029 ORM-6151 ORM-1153 Antigen HER2 CD33 CD123 ORM-1153 Design Goals Indication Breast cancer AML, HR-MDS Based on Clinical AML, HR-MDS, CMML, B-ALL, Learnings MPAL, BPDCN Wild Type IgG1 IgG1 Fc-silenced; Antibody pertuzumab biosimilar uses gemtuzumab CD
Slide 14: ORM-1153 Antibody Internalization Supports a Delivery Hypothesis
ORM-1153 Antibody Internalization Supports a Delivery Hypothesis In preclinical models, enhanced internalization was associated with stronger activity than the comparator construct Internalization efficiency in MV-4-11 (24 hrs) Disseminated MV-4-11-Luc xenograft mouse model BLI (photons/sec) 5000 Ve
Slide 15: ORM-1153 Exhibits CD123-Dependent Activity and Strong Potency in AML Cell Lines
ORM-1153 Exhibits CD123-Dependent Activity and Strong Potency in AML Cell Lines CD123-dependent cytotoxicity in CD123+/- AML cells Comparative potency against SoC agents in MV-4-11 125 125 ORM-1153 ORM-1153 ORM-1153 100 MV-4-11 100 Venetoclax SMol006* CD123+ venetoclax % viability % viability Gemtuz
Slide 16: Robust Tumor Control and Survival Benefit of ORM-1153 in Disseminated AML Model
Robust Tumor Control and Survival Benefit of ORM-1153 in Disseminated AML Model ORM-1153 drives greater reduction in tumor burden and robust survival compared to SoC and benchmark ADC Disseminated MV4-11-Luc xenograft mouse model Greater reduction in AML burden over time 93% tumor reduction at Day 1
Slide 17: ORM-1153 Potently Inhibits Growth in AML TP53 Isogenic Cell Lines
ORM-1153 Potently Inhibits Growth in AML TP53 Isogenic Cell Lines Activity in TP53 knockout cells supports evaluation across genetic backgrounds; patient activity remains to be tested MV-4-11 TP53 WT/KO cells ORM-1153 Venetoclax Pivekimab sunirine (DecnupazTM) Pivekimab-SMol249* 150 MV-4-11 150 150
Slide 18: ORM-1153 Exhibits Sub-nanomolar Ex Vivo Anti-Leukemic Activity
ORM-1153 Exhibits Sub-nanomolar Ex Vivo Anti-Leukemic Activity ORM-1153 showed greater ex vivo potency than ORM-6151 in selected patient-derived models CTG2704 CTG2240 CTG2227 CTG3440 ORM-1153 ORM-6151 2023 AACR Abstract #2700; 2026 AACR Abstract #1710 18 ORUM THERAPEUTICS
Slide 19: NHP Study Provides a Starting Point for Clinical Safety Assessment
NHP Study Provides a Starting Point for Clinical Safety Assessment At the 6 mg/kg NHP NHSTD, repeat dosing produced transient, reversible AST/ALT elevations Liver enzymes Exposure-based preclinical therapeutic window AST Exposure Based Preclinical Vehicle control ORM-1153 6mg/kg *Normal TI for ORM-1
Slide 20: ORM-1153 Phase 1: First-in-Human Dose Escalation
ORM-1153 Phase 1: First-in-Human Dose Escalation First-in-human study evaluating safety, PK/PD and preliminary activity in R/R AML and other CD123- expressing hematologic malignancies Methodology Phase 1 Dose Escalation (NCT07809906) Open-label, multiregional, Phase 1 dose escalation CD123 expressin
Slide 21: ORM-1153: Key Highlights & Next Steps
ORM-1153: Key Highlights & Next Steps Differentiated Supportive Phase 1 study underway CD123-directed design preclinical evidence Leverages CD123 expression on AML Anti-leukemic activity across AML First patient dosed; dose escalation blasts and leukemic stem cells, with models and repeat-dose NHP t
Slide 22: ORM-1023: GSPT1-DAC for Small Cell Lung Cancer and Neuroendocrine Tumors
ORM-1023: GSPT1-DAC for Small Cell Lung Cancer and Neuroendocrine Tumors Combining targeted delivery with GSPT1 degradation Antigen target: Antibody Undisclosed Orum discovered Fc-silenced antibody against an undisclosed tumor antigen Indication: Small cell lung cancer (SCLC), Neuroendocrine tumors
Slide 23: Robust In Vivo Activity of ORM-1023 in SCLC PDX Model
Robust In Vivo Activity of ORM-1023 in SCLC PDX Model Single-dose ORM-1023 demonstrated tumor growth inhibition across multiple SCLC PDX models In vivo activity of ORM-1023 in SCLC PDX model* LU5242 – Tumor Volume LU5242 – Body Weight Vehicle ORM-1023 1 mg/kg 800 ORM-1023 3 mg/kg 40 Tumor volume (mm
Slide 24: New Payload Platform
New Payload Platform Expanding DAC payloads beyond GSPT1
Slide 25: Orum's Proprietary DAC Platforms: Potential Across Multiple Indications
Orum's Proprietary DAC Platforms: Potential Across Multiple Indications Modular platform technology allows for creation of a multitude of targeted therapies ● Orum's strength lies in its ability to develop the antibody and degrader payload separately, tailoring these components to enhance therapeuti
Slide 26: Structure-based Discovery Workflow at Orum: From Target to Lead Candidate
Structure-based Discovery Workflow at Orum: From Target to Lead Candidate Protein of interest Co-crystal vs. AI prediction AI-based E3 ternary complex modeling E3 ligase AI prediction ination B. V rm irtu Dete al S Warhead e PROTAC linker screening cr r Electron density map Linker tu ee uc AI or exp
Slide 27: PROTAb Linker Adapter Platform to Facilitate the Development of DACs
PROTAb Linker Adapter Platform to Facilitate the Development of DACs Adaptor for E3 ligase-based degrader conjugation PROTAb-enabled traceless conjugation process Step 1. PROTAb attachment to ADC linker PROTAb Step 3. Intracellular Linker Step 2. Conjugation to E3-ligase degrader traceless release R
Slide 28: PROTAb Enables Targeted Degradation with Diverse Hetero-Bifunctional Degraders
PROTAb Enables Targeted Degradation with Diverse Hetero-Bifunctional Degraders Demonstrates effective use of PROTAb with non-GSPT1 targets and hetero-bifunctional degraders POC molecules PROTAb-DACs are BCMA-BRD4 Targeted BRD4 degradation drives cytotoxicity highly effective in vitro Anti-BCMA mAb M
Slide 29: Novel DAC Payloads Show In Vivo Activity in Solid-Tumor Models
Novel DAC Payloads Show In Vivo Activity in Solid-Tumor Models Early preclinical evidence supports continued development of novel degrader payloads for solid tumors Proprietary Hit Payloads Conjugated to Tool Antibody, DAR8 1500 1500 Breast cancer CDX Gastric cancer CDX Tumor volume (mm3) 1500 1500
Slide 30: Orum's Strategic Partnering Approach
Orum's Strategic Partnering Approach Distinct partnering strategies aligned with program maturity and development progress 1 2 3 ORM-1153 New Payload Platforms External Opportunities Solid Tumors Scout technologies and Continue engagement with Explore single or multi-program programs that complement
Slide 31: Thank you
Thank you A world where no patients suffer from diseases caused by undruggable targets www.orumrx.com